Sentences with phrase «by studying drug»

Wu focused on the big picture by studying drug response and drug reaction.

Not exact matches

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

A peer - reviewed study by researchers at the University of British Columbia and Simon Fraser University, published recently in The International Journal of Drug Policy, pegged the retail value of marijuana consumption in B.C. alone at between $ 443 million and $ 564 million.

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

Studies commissioned by his group project that over the next decade, PBMs will save employers, consumers, and the government more than $ 2 trillion, and have already helped reduce by a third the projected cost of the Medicare Part D program, a largely privatized drug benefit for seniors.

In a new study based on mice, scientists at Lancaster University found that a drug that goes after three diabetes - related targets «significantly reversed the memory deficit» in mice who got the drug, as measured by their performance in a maze test when compared to mice who didn't get the drug.

After that, Watson will take assist by providing both physician and patient with a report that includes the most relevant drug trial and academic studies for their specific conditions.

After fighting unsuccessfully to reverse generic drug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrdrug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher InterbrDrug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrand.

«By having 1 million individual users you can get to a scale where researchers are running data queries through 23andMe, where drug studies leverage our data, and where individuals can more easily be connected to studies that could benefit them,» Wojcicki said.

According to a 2015 research study in the Journal of American Medical Association, many new drugs approved by the Food and Drug Administration don't improve overall survival.

They've conducted studies in mice, which showed that the device was able to improve the results of the drug by twelve times.

According to a study published last year by the National Bureau of Economic Research, American consumers are spending an estimated extra $ 44 billion a year on brand - name drugs, health care items and pantry goods.

Phase I funding — which allows up to $ 250,000 for an academic idea, such as decoding the genetic sequence of a protein or studying targeted drug delivery by using magnetic nanoparticles — is available from federal funding and foundations.

Studies have found that longer sentences do not have appreciably greater deterrent effects; many serious crimes are committed by people under the influence of alcohol or drugs, who are not necessarily thinking of the consequences of their actions, and certainly are not affected by the difference between a 15 - year and a 30 - year sentence.

The drug is called Acthar, and for the past year it has been the focus of a study by the Oregon Health and Science University School of Medicine and Oregon State that has been trying to understand why doctors keep prescribing it for ailments it has never been proved to treat effectively.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

A 2000 study by University of Chicago economics professor Steven Levitt and Columbia University sociology professor Sudhir Venkatesh found that the availability of drugs and their prices fell by 20 to 30 percent during gang conflicts.

The drug known by the street names Ecstasy or Molly could be a promising treatment for post-traumatic stress disorder, according to a new study.

Directing emergency funds to areas hit by natural disasters had traditionally been quick bipartisan exercises, but that changed after Hurricane Katrina in 2005 — when the Republican Study Committee, a group of House conservatives, pushed spending cuts to compensate for the approximately $ 200 billion expected in Katrina relief — including cutting farm subsidies, Amtrak funding and postponing the Medicare prescription - drug bill Republicans had approved two years earlier.

Alnylam, which has been weighed down in the past by drug safety concerns, said it plans to initiate a program targeting cardiomyopathy - another symptom of the disease - alongside polyneuropathy in a late - stage study next year.

(Reuters)- Alnylam Pharmaceuticals Inc's RNAi - based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease - causing proteins.

«Not many people,» Elliott notes, «feel a moral duty to take part in these studies»» though, of course, we are more than happy to reap the benefits brought by new drugs.

Another study from Nigeria published in December of 2017 is titled Antioxidant and anti-inflammatory effects of virgin coconut oil supplementation abrogate acute chemotherapy oxidative nephrotoxicity induced by anticancer drug methotrexate in rats.

Alarmed by DMSO's sudden popularity and worried about misuse of it, the U.S. Food and Drug Administration banned the substance for medical use in 1965, citing a study that suggested it caused eye damage in laboratory rats.

To overcome the drowsiness caused by sleep deprivation, many kids resort to taking «study drugs» like Adderall (meant for kids with ADHD), which can impair long - term learning and can produce fatal arrhythmias.

In a study by Oo, Kuhn, and Desai, in Br J Clin Pharmacol, looking at the maternal levels of alprazolam in mothers» breast milk after a daily dose of 0.5 mg of the drug, they found that the half - life of alprazolam in the milk is long: 14.5 hours, more than half a day.

See the practice section for a case study highlighting a service in Sheffield that supports fathers affected by problematic drug use in their family.

scientific study has learneed that the benzodiazepine drug treatments, the actual Valiums along with Xanaxes, perform how they do by interesting any natural chemical called «gamma - aminobutyric acid, or even Gamma aminobutyric acid, therefore selling a relaxing impact in only exactly the same as the highly habit forming opioids.

Other studies show children who have limits and rules enforced reasonably, are less likely to get involved in drugs and juvenile crime, whereas children raised by authoritarian, harsh parenting or overly permissive parenting, had a higher risk.

If however many MDs aren't practicing evidence - based medicine, then why not don't MDs * police their own * before going off on other professions for their lack of evidence - base... or attacking what evidence - base there is even if it isn't multiple double - blind placebo controlled studies funded by wealthy drug manufacturers?

Funding / Support: The Infant Feeding Practices Study II was funded by the Food and Drug Administration, Centers for Disease Control and Prevention, Office of Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services.

The Infant Feeding Practices Study II is a longitudinal study of new mothers and their infants conducted by the Food and Drug Administration and the Centers for Disease Control and Prevention from May 2005 to June Study II is a longitudinal study of new mothers and their infants conducted by the Food and Drug Administration and the Centers for Disease Control and Prevention from May 2005 to June study of new mothers and their infants conducted by the Food and Drug Administration and the Centers for Disease Control and Prevention from May 2005 to June 2007.

For the purposes of this economic evaluation, the forms were initially used in a related study funded by the National Institute of Health Research (NIHR) research for patient benefit programme «assessing the impact of a new birth centre on choice and outcome of maternity care in an inner city area,» which will be reported in full elsewhere, comparing the costs of care in a free standing midwifery unit with care in an obstetric unit in the same trust.16 The data collected included details of staffing levels, treatments, surgeries, diagnostic imaging tests, scans, drugs, and other resource inputs associated with each stage of the pathway through intrapartum and after birth care.

It would be unethical to conduct a controlled study that might put a baby at risk by deliberately giving the breastfeeding mother drugs.

The purpose of this study was to examine weight gain in infants who are breastfed by mothers who take fluoxetine during pregnancy and after birth, compared with infants breastfed by mothers who have taken the drug sometime during pregnancy but not during the breastfeeding period.

These are some of the recommendations contained in a study produced by Spanish researchers on methods for detecting medicines and drugs in breast milk.

She also instinctively bends her legs completing the protective space around the baby, making it impossible for another person to roll onto the baby without first coming into contact with her legs.15, 16 A breastfeeding mother who co-sleeps with her baby (and has not consumed alcohol, illegal or sleep - inducing drugs or extreme fatigue) also tends to be highly responsive to her baby's needs.17, 18 Studies show more frequent arousals in both mothers and babies when they co-sleep, and some researchers have suggested that this may be protective against sudden unexpected infant deaths.19 — 21 Babies are checked by their mother and breastfeed more frequently when co-sleeping than when room - sharing.22, 23

After much petitioning by the Center for Science in the Public Interest (CSPI), The Food and Drug Administration (FDA) has announced plans to form an advisory committee meeting which will review clinical studies conducted on common food dyes including Yellow 5 and Red 40 and the link connecting them to adverse behavior issues in children.

Physical punishment is associated with a range of mental health problems in children, youth and adults, including depression, unhappiness, anxiety, feelings of hopelessness, use of drugs and alcohol, and general psychological maladjustment.26 — 29 These relationships may be mediated by disruptions in parent — child attachment resulting from pain inflicted by a caregiver, 30,31 by increased levels of cortisol32 or by chemical disruption of the brain's mechanism for regulating stress.33 Researchers are also finding that physical punishment is linked to slower cognitive development and adversely affects academic achievement.34 These findings come from large longitudinal studies that control for a wide range of potential confounders.35 Intriguing results are now emerging from neuroimaging studies, which suggest that physical punishment may reduce the volume of the brain's grey matter in areas associated with performance on the Wechsler Adult Intelligence Scale, third edition (WAIS - III).36 In addition, physical punishment can cause alterations in the dopaminergic regions associated with vulnerability to the abuse of drugs and alcohol.37

This study, performed by Swansea University researchers of 48,000 women who gave birth to healthy (singleton) babies over 10 years, found that women who took these drugs had a 7 % chance of lowered milk production.

Since there is no money to be made by drug companies, I doubt there will ever be more than antidotial studies on the benefits, unfortunately for many mothers who would have benefited.

Two puffed grain rice snacks were tested by the US Food and Drug Administration; the banana flavor had a total As concentration of 109 ng / g (46 ng / g inorganic), and the blueberry flavor was below the limit of quantitation of 3 ng / g.45 In the study by Signes - Pastor et al, 10 As concentrations in 97 rice crackers from 15 different brands ranged from 19 to 246 ng / g, with inorganic As ranging from 19 to 212 ng / g.

Mrs. Alarbi said studies showed that for babies born to HIV - infected mothers, the use of niverapine drug combined with baby formulas to prevent mother - to - child transmission, could reduce child mortality to only two per cent of under - five mortality and morbidity while the use of insecticide - treated bed nets could reduce it by six per cent.

Many women don't want to deliver in a hospital because they fear their choices — to avoid drugs, to avoid surgery, to be surrounded by their families, to be with the baby immediately after delivery — will be taken away, said Carolyn L. Gegor, program director of the Nurse Midwifery / Women's Health Nurse Practitioner Program in the School of Nursing and Health Studies at Georgetown University Medical Center.

This can be seen starkly in the results of a new study, published in the journal Drug Test Analysis and carried out by scientists at King's College London.

A study commissioned by the Pharmaceutical Research and Manufacturers of America — the trade organization representing the drug industry — warns that Cuomo's plan will drive up health care costs, harm New York consumers and could worsen the addiction crisis.

A 2012 study published by the Mayo Clinic found that users of marijuana have a smaller chance of developing an addiction to the drug than users of alcohol or tobacco.

A recent study found that Onondaga County has a higher rate of deaths by drug overdose than New York state and the United States.

He has previously suggested marijuana is a «gateway drug» — a claim disputed by those who have studied drug policy and addiction.